These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 37081608)

  • 21. Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts.
    Thompson J; George EO; Poquette CA; Cheshire PJ; Richmond LB; de Graaf SS; Ma M; Stewart CF; Houghton PJ
    Clin Cancer Res; 1999 Nov; 5(11):3617-31. PubMed ID: 10589779
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II study of irinotecan in combination with temozolomide (TEMIRI) in children with recurrent or refractory medulloblastoma: a joint ITCC and SIOPE brain tumor study.
    Grill J; Geoerger B; Gesner L; Perek D; Leblond P; Cañete A; Aerts I; Madero L; de Toledo Codina JS; Verlooy J; Estlin E; Cisar L; Breazna A; Dorman A; Bailey S; Nicolin G; Grundy RG; Hargrave D;
    Neuro Oncol; 2013 Sep; 15(9):1236-43. PubMed ID: 23857707
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of food on the pharmacokinetics of the WEE1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumors.
    Någård M; Ah-See ML; So K; Vermunt M; Thistlethwaite F; Labots M; Roxburgh P; Ravaud A; Campone M; Valkenburg-van Iersel L; Ottesen L; Li Y; Mugundu G
    Cancer Chemother Pharmacol; 2020 Jul; 86(1):97-108. PubMed ID: 32556602
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase I trial of metformin in combination with vincristine, irinotecan, and temozolomide in children with relapsed or refractory solid and central nervous system tumors: A report from the national pediatric cancer foundation.
    Metts JL; Trucco M; Weiser DA; Thompson P; Sandler E; Smith T; Crimella J; Sansil S; Thapa R; Fridley BL; Llosa N; Badgett T; Gorlick R; Reed D; Gill J
    Cancer Med; 2023 Feb; 12(4):4270-4281. PubMed ID: 36151773
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination of bevacizumab, irinotecan, and temozolomide for refractory or relapsed neuroblastoma: Results of a phase II study.
    Modak S; Kushner BH; Basu E; Roberts SS; Cheung NK
    Pediatr Blood Cancer; 2017 Aug; 64(8):. PubMed ID: 28111925
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oxaliplatin, irinotecan, and gemcitabine: a novel combination in the therapy of progressed, relapsed, or refractory tumors in children.
    Hartmann C; Weinel P; Schmid H; Grigull L; Sander A; Linderkamp C; Welte K; Reinhardt D
    J Pediatr Hematol Oncol; 2011 Jul; 33(5):344-9. PubMed ID: 21572345
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical Efficacy and Molecular Response Correlates of the WEE1 Inhibitor Adavosertib Combined with Cisplatin in Patients with Metastatic Triple-Negative Breast Cancer.
    Keenan TE; Li T; Vallius T; Guerriero JL; Tayob N; Kochupurakkal B; Davis J; Pastorello R; Tahara RK; Anderson L; Conway J; He MX; Shannon E; Godin RE; Sorger PK; D'Andrea A; Overmoyer B; Winer EP; Mittendorf EA; Van Allen EM; Shapiro GI; Tolaney SM
    Clin Cancer Res; 2021 Feb; 27(4):983-991. PubMed ID: 33257427
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Upregulation of Myt1 Promotes Acquired Resistance of Cancer Cells to Wee1 Inhibition.
    Lewis CW; Bukhari AB; Xiao EJ; Choi WS; Smith JD; Homola E; Mackey JR; Campbell SD; Gamper AM; Chan GK
    Cancer Res; 2019 Dec; 79(23):5971-5985. PubMed ID: 31594837
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ADAGIO: a phase IIb international study of the Wee1 inhibitor adavosertib in women with recurrent or persistent uterine serous carcinoma.
    Liu J; Oza AM; Colombo N; Oaknin A
    Int J Gynecol Cancer; 2022 Jan; 32(1):89-92. PubMed ID: 34716177
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vincristine, irinotecan, and temozolomide treatment for refractory/relapsed pediatric solid tumors: A single center experience.
    Büyükkapu Bay S; Kebudi R; Görgün O; Zülfikar B; Darendeliler E; Çakır FB
    J Oncol Pharm Pract; 2019 Sep; 25(6):1343-1348. PubMed ID: 30080131
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-Effectiveness Analysis of a Three-Drug Regimen Containing Bevacizumab for the Treatment of Recurrent Pediatric
    Chen Z; Tian F; Chen X
    Front Public Health; 2022; 10():914536. PubMed ID: 35719637
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Response to bevacizumab, irinotecan, and temozolomide in children with relapsed medulloblastoma: a multi-institutional experience.
    Aguilera D; Mazewski C; Fangusaro J; MacDonald TJ; McNall-Knapp RY; Hayes LL; Kim S; Castellino RC
    Childs Nerv Syst; 2013 Apr; 29(4):589-96. PubMed ID: 23296323
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase 1 and pharmacokinetic study of concurrent carboplatin and irinotecan in subjects aged 1 to 21 years with refractory solid tumors.
    Levy AS; Meyers PA; Wexler LH; Jakacki R; Angiolillo A; Ringuette SN; Cohen MB; Gorlick R
    Cancer; 2009 Jan; 115(1):207-16. PubMed ID: 19090012
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring
    Fu S; Yao S; Yuan Y; Previs RA; Elias AD; Carvajal RD; George TJ; Yuan Y; Yu L; Westin SN; Xing Y; Dumbrava EE; Karp DD; Piha-Paul SA; Tsimberidou AM; Ahnert JR; Takebe N; Lu K; Keyomarsi K; Meric-Bernstam F
    J Clin Oncol; 2023 Mar; 41(9):1725-1734. PubMed ID: 36469840
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study.
    Wagner LM; Villablanca JG; Stewart CF; Crews KR; Groshen S; Reynolds CP; Park JR; Maris JM; Hawkins RA; Daldrup-Link HE; Jackson HA; Matthay KK
    J Clin Oncol; 2009 Mar; 27(8):1290-6. PubMed ID: 19171709
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Phase I Trial of TB-403 in Relapsed Medulloblastoma, Neuroblastoma, Ewing Sarcoma, and Alveolar Rhabdomyosarcoma.
    Saulnier-Sholler G; Duda DG; Bergendahl G; Ebb D; Snuderl M; Laetsch TW; Michlitsch J; Hanson D; Isakoff MS; Bielamowicz K; Kraveka JM; Ferguson W; Carmeliet P; De Deene A; Gijsen L; Jain RK
    Clin Cancer Res; 2022 Sep; 28(18):3950-3957. PubMed ID: 35833850
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Wee1 kinase inhibitor adavosertib with radiation in newly diagnosed diffuse intrinsic pontine glioma: A Children's Oncology Group phase I consortium study.
    Mueller S; Cooney T; Yang X; Pal S; Ermoian R; Gajjar A; Liu X; Prem K; Minard CG; Reid JM; Nelson M; Haas-Kogan D; Fox E; Weigel BJ
    Neurooncol Adv; 2022; 4(1):vdac073. PubMed ID: 35733515
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial.
    DuBois SG; Marachelian A; Fox E; Kudgus RA; Reid JM; Groshen S; Malvar J; Bagatell R; Wagner L; Maris JM; Hawkins R; Courtier J; Lai H; Goodarzian F; Shimada H; Czarnecki S; Tsao-Wei D; Matthay KK; Mosse YP
    J Clin Oncol; 2016 Apr; 34(12):1368-75. PubMed ID: 26884555
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomized Phase II Trial of Vincristine-Irinotecan With or Without Temozolomide, in Children and Adults With Relapsed or Refractory Rhabdomyosarcoma: A European Paediatric Soft Tissue Sarcoma Study Group and Innovative Therapies for Children With Cancer Trial.
    Defachelles AS; Bogart E; Casanova M; Merks JHM; Bisogno G; Calareso G; Gallego Melcon S; Gatz SA; Le Deley MC; McHugh K; Probst A; Rocourt N; van Rijn RR; Wheatley K; Minard-Colin V; Chisholm JC
    J Clin Oncol; 2021 Sep; 39(27):2979-2990. PubMed ID: 34343032
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II Study of the WEE1 Inhibitor Adavosertib in Recurrent Uterine Serous Carcinoma.
    Liu JF; Xiong N; Campos SM; Wright AA; Krasner C; Schumer S; Horowitz N; Veneris J; Tayob N; Morrissey S; West G; Quinn R; Matulonis UA; Konstantinopoulos PA
    J Clin Oncol; 2021 May; 39(14):1531-1539. PubMed ID: 33705205
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.